A Look At The Intrinsic Value Of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)
Key Insights Zentalis Pharmaceuticals' estimated fair value is US$9.86 based on 2 Stage Free Cash Flow to Equity Current share price of US$9.99 suggests Zentalis Pharmaceuticals is potentially tradi
Stifel Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $32
Stifel analyst Bradley Canino maintains $Zentalis Pharmaceuticals(ZNTL.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 41.8%
Express News | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ...
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
NEW YORK and SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small
Express News | Zentalis Pharmaceuticals Inc -on and Effective May 24, Board Increased Its Size From Six to Seven Directors
Express News | Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.d., to Board of Directors
Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial
Zentalis Pharmaceuticals (ZNTL) said final results from a phase 1 trial of azenosertib plus gemcitabine in relapsed or refractory osteosarcoma resulted in clinically meaningful increase in event-free
Zentalis Pharmaceuticals to Present Promising Results From Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced the presentation of final results from a Phase 1 trial of azenosertib and gemcitabine in relapsed or refractory (R/R) osteosarcoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
NEW YORK and SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small
Assessing Zentalis Pharmaceuticals: A Balanced Hold Rating Amidst Financial Stability and Uncertain Market Prospects
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Zentalis Pharmaceuticals (ZNTL) and Paragon 28 (FNA)
Buy Rating on Zentalis Pharmaceuticals Amid High Expectations for Azeno Drug Trials
Stifel Nicolaus Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals Price Target Cut to $40.00/Share From $46.00 by HC Wainwright & Co.
Zentalis Pharmaceuticals Price Target Cut to $40.00/Share From $46.00 by HC Wainwright & Co.
Zentalis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Zentalis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Zentalis Pharma, Lowers Price Target to $40
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating
Zentalis Pharmaceuticals (ZNTL) has an average outperform rating and a price target range of $15 to $50, according to analysts polled by Capital IQ. Price: 12.06, Change: -0.25, Percent Change: -2.03
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) instance, it's good news for shareholders.
Zentalis Pharmaceuticals Price Target Cut to $32.00/Share From $36.00 by Stifel
Zentalis Pharmaceuticals Price Target Cut to $32.00/Share From $36.00 by Stifel
No Data